SCHEMBL20399017

SCHEMBL20399017

FC(F)(F)c1ncccc1CNc1nc(N2CCCC(C(F)(F)F)C2)nc2ncccc12

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 3/20 0.42
PIP4K2C Q8TBX8 1/20 0.36
PTPN11 Q06124 3/20 0.36
KDM4E B2RXH2 2/20 0.35
CD38 P28907 1/20 0.35
CDK1 P06493 1/20 0.34
MTOR P42345 1/20 0.34
ACACB O00763 1/20 0.34
MAP4K4 O95819 1/20 0.34
TRPV3 Q8NET8 1/20 0.34
TRPV1 Q8NER1 2/20 0.34
USP2 O75604 1/20 0.33
LMNA P02545 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21541964 0.95 CCR4 (0.41) CCR4PIP4K2CPTPN11CD38
SCHEMBL29737552 0.95 CCR4 (0.41) CCR4PIP4K2CPTPN11CD38
SCHEMBL21542018 0.91 CCR4 (0.40) CCR4PIP4K2CPTPN11KDM4ECD38
SCHEMBL21542047 0.89 TRPV1 (0.43) CCR4PIP4K2CPTPN11KDM4ECD38
SCHEMBL21567328 0.89 CCR4 (0.42) CCR4PIP4K2CPTPN11CD38TRPV1
SCHEMBL29737529 0.89 CCR4 (0.42) CCR4PIP4K2CPTPN11CD38TRPV1
SCHEMBL21541983 0.89 CCR4 (0.44) CCR4PIP4K2CPTPN11KDM4ECD38
SCHEMBL21542061 0.89 CCR4 (0.43) CCR4PIP4K2CPTPN11KDM4ECD38
SCHEMBL20399010 0.88 CCR4 (0.45) CCR4PIP4K2CKDM4ECD38TRPV1
SCHEMBL20399571 0.88 CCR4 (0.45) CCR4PIP4K2CKDM4ECD38TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108629-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) 2024-04-04 US claimed
EP-4277631-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL Liverpool School of Tropical Medicine (GB) 2023-11-22 EP claimed
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2022-12-06 US claimed
WO-2022152918-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2022-07-21 WO claimed
US-20190345157-A1 COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-11-14 US claimed
WO-2018134685-A2 COMPOUNDS LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2018-07-26 WO claimed
US-12545675-B2 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2026-02-10 US disclosed
US-20240108629-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) 2024-04-04 US disclosed
EP-4277631-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL Liverpool School of Tropical Medicine (GB) 2023-11-22 EP disclosed
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS THE UNIVERSITY OF LIVERPOOL (GB) 2023-11-02 US disclosed
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS THE UNIVERSITY OF LIVERPOOL (GB) 2023-11-02 US disclosed
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2022-12-06 US disclosed
WO-2022152918-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) 2022-07-21 WO disclosed
US-20190345157-A1 COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-11-14 US disclosed
US-20190345157-A1 COMPOUNDS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545675-B2 Anti-wolbachia pyrido[2,3-d]pyrimidine compounds CBR1, CBR3, COX6C CCR4 101/4885PIP4K2C 2323/4885PTPN11 655/4885
US-20230348460-A1 ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS PWWP2B, WARS1, PNPO CCR4 3571/4885PIP4K2C 298/4885PTPN11 480/4885
US-20190345157-A1 COMPOUNDS ABCB11, LTC4S, AQP1 CCR4 752/4885PIP4K2C 3380/4885PTPN11 3665/4885
US-11518760-B2 Anti-Wolbachia pyrido[2,3-d]pyrimidine compounds P2RX5, PNPO, P2RX3 CCR4 3139/4885PIP4K2C 221/4885PTPN11 558/4885
US-20240108629-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL AQP3, AQP1, AQP4 CCR4 2777/4885PIP4K2C 2488/4885PTPN11 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.